UPSA SAS
UPSA SAS is a 1935-founded French pharmaceutical laboratory, wholly owned by Taisho Pharmaceutical Group, that manufactures and distributes self-medication drugs, medical devices, and dietary supplements across six therapeutic areas (pain, ORL, digestion, sleep, vitality, women's health) through pharmacies in 10 countries.
- Company typePrivate
- Founded1935
- HeadquartersRueil-malmaison, France
- Headcount1,001–5,000
- GTM typeB2C
- OfferingHardware or Manufacturing
UPSA SAS firmographics
Firmographics- Name
- UPSA SAS
- Legal name
- UPSA SAS
- Website
- https://upsa.com
- Company type
- Private
- Founded year
- 1935
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- UPSA SAS is a 1935-founded French pharmaceutical laboratory, wholly owned by Taisho Pharmaceutical Group, that manufactures and distributes self-medication drugs, medical devices, and dietary supplements across six therapeutic areas (pain, ORL, digestion, sleep, vitality, women's health) through pharmacies in 10 countries.
- Ownership category
- akta.pro rank
UPSA SAS industry classification
Industry- Product category
- Consumer Pharmaceuticals (OTC / Self-Medication)
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Women’s Health Supplements (Prenatal, Menopause, Hormonal) (CRADAGAK)
- akta.pro secondary industry
- Specialty Condition Supplements (Sleep, Stress, Heart, Joint, Gut, Immunity) (CRADAGAE)
Keywords
Where UPSA SAS is headquartered
LocationHeadquarters
- HQ city
- Rueil-malmaison
- HQ country
- France
- HQ region
- Europe
Offices13 records
Markets served
UPSA SAS business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical product sales: UPSA generates revenue through the sale of self-medication pharmaceutical products, medical devices, and dietary supplements across six therapeutic areas: pain and fever, ORL/respiratory, digestion, sleep, vitality, and women's health. Products are distributed through pharmacies and sold to patients seeking treatment for minor everyday ailments.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
UPSA SAS product offering
Product offeringCore offering
UPSA SAS is a French pharmaceutical laboratory that develops, manufactures, and distributes self-medication (OTC) pharmaceutical products, medical devices, and dietary supplements across six therapeutic areas: pain and fever, ORL/respiratory, digestion, sleep, vitality, and women's health. Products are sold through pharmacies and target patients with minor everyday ailments, with the flagship DAFALGAN® paracetamol brand in pain/fever and the Sérélys® dietary supplement line in women's health following the 2024 acquisition of Sérélys Pharma.
Product overview
UPSA SAS is a French pharmaceutical laboratory founded in 1935, operating as both a mid-sized company (ETI) with major industrial sites in Agen, France and an established brand serving patients and pharmacists for over 90 years. The company offers a portfolio of self-medication products, medical devices, and dietary supplements spanning six therapeutic areas: pain and fever (including the historic DAFALGAN® paracetamol brand), ORL/respiratory, digestion, sleep disorders, vitality, and women's health. Following the July 2025 acquisition of Sérélys Pharma, the company expanded into the women's health dietary supplement market with the Sérélys® product line including SERELYS® PMS, OSTEO, NIGHT, MENO, MAN, and INCO CONTROL. All medicines carry the Origine France Garantie certification, and the company is B Corp certified.
Differentiator
Problem solved
Functional benefit
Brands
- Dafalgan: Pain and fever relief medication containing paracetamol
- Sérélys
- Institut UPSA de la Douleur
Products and services
- DAFALGAN® 1000 mg Paracetamol-based pain and fever relief medication in film-coated tablet form. Manufactured in France, reimbursable, and indicated for patients seeking OTC pain and fever relief.
- Sérélys® PMS Dietary supplement formulated with natural ingredients to support women's health during premenstrual syndrome. Available in pharmacies as part of the Sérélys® women's health line.
- Sérélys® OSTEO Dietary supplement supporting bone health in women, part of the Sérélys® women's health line acquired by UPSA.
- Sérélys® NIGHT Dietary supplement with purified pollen extracts, melatonin, and marine magnesium to help restore sleep and serenity during menopause and perimenopause.
- Sérélys® MENO Non-hormonal dietary supplement with PureCyTonin® pollen extracts and vitamin E for women in perimenopause or menopause to reduce hot flashes.
- Sérélys® MAN Dietary supplement formulated to reduce hot flashes in men during andropause or medical treatments, containing PureCyTonin® complex and vitamin E.
- Sérélys® INCO CONTROL Dietary supplement with UriCyTonin® pollen complex, pumpkin seed extract, and vitamin E to help women reduce urinary leaks and improve bladder control.
Companies that use UPSA SAS
Customer profileSegments2 records
Ideal customer profiles2 records
UPSA SAS technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
UPSA SAS partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and minor.
- Sérélys PharmacoreUPSA acquired Sérélys Pharma, a leading French company specializing in women's health products. The acquisition includes the Sérélys product line of dietary supplements for women's health including PMS, menopause, and bladder control solutions.
- e-Nable FranceminorPartnership with e-Nable France, an association that uses 3D printing technology for solidarity purposes. Collaboration discovered through a colleague in the retail sector.
Scale indicators3 records
Recent moves6 records
Expansion highlights6 records
UPSA SAS competitors and assessment
Company assessmentDirect peers
- Perrigo Company: US-headquartered OTC and self-care company operating a large store-brand and branded OTC portfolio across Europe; directly comparable in pharmacy distribution and OTC therapeutic breadth.
- Bayer AG: Global pharma and consumer health company with leading OTC franchises (Aspirin, Claritine, Bepanthen) sold through pharmacies; directly comparable to UPSA in self-medication distribution model and therapeutic breadth.
- Pierre Fabre: French privately-held pharmaceutical and dermo-cosmetics company with consumer health products sold through pharmacies; directly comparable to UPSA in French OTC manufacturing and pharmacy channel model.
- Sanofi: French-headquartered global pharmaceutical company with a large Consumer Healthcare (OTC) division including Doliprane (paracetamol), directly competing with UPSA in French self-medication and across European OTC categories.
- Haleon: Pure-play consumer healthcare company spun out of GSK (Panadol, Voltaren, Centrum) operating across pain, respiratory, and supplements; one of the closest pure OTC comparables to UPSA's therapeutic portfolio and pharmacy channel.
- Johnson & Johnson (McNeil Consumer Healthcare): Owner of Tylenol, the leading paracetamol-based OTC pain brand globally; directly comparable to UPSA in core pain/fever self-medication category and pharmacy distribution model.
Emerging players
- Cooper Consumer Health: European-focused OTC platform that has been actively acquiring mid-sized European self-medication brands; comparable to UPSA as a mid-sized European OTC specialist pursuing buy-and-build expansion.
- Pileje: French privately-held dietary supplement specialist with a broad women's health and gut health range sold through pharmacies; comparable to UPSA's Sérélys line and supplement distribution in French pharmacy channel.
Regional players
- Zambon: Italian privately-held pharmaceutical company with OTC and specialty pharma operations across Europe; comparable to UPSA as a mid-sized European pharma with pharmacy distribution and international subsidiary structure.
Broad incumbents
- Merck KGaA: German diversified science and healthcare group with consumer health and OTC exposure including Seven Seas supplements; comparable to UPSA's pharmaceutical manufacturing and dietary supplement operations in Europe.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
UPSA SAS social profiles
Digital presenceUPSA SAS compliance and trust
Trust signalCompliance3 records
UPSA SAS financial estimates
Financial estimateRevenue estimate
Valuation estimate
UPSA SAS leadership team
Management profileNumber of profiles
Profiles4 records
UPSA SAS subsidiaries and ownership
Company hierarchySubsidiaries15 records
UPSA SAS funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
UPSA SAS M&A and investment
M&A and investmentM&A
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about UPSA SAS
What does UPSA SAS do?
UPSA SAS is a French pharmaceutical laboratory that develops, manufactures, and distributes self-medication (OTC) pharmaceutical products, medical devices, and dietary supplements across six therapeutic areas: pain and fever, ORL/respiratory, digestion, sleep, vitality, and women's health. Products are sold through pharmacies and target patients with minor everyday ailments, with the flagship DAFALGAN® paracetamol brand in pain/fever and the Sérélys® dietary supplement line in women's health following the 2024 acquisition of Sérélys Pharma.
Is UPSA SAS a public or private company?
UPSA SAS is a private company. It is classified as corporate owned and is currently operating.
When was UPSA SAS founded?
UPSA SAS was founded in 1935. It employs 1,001 to 5,000 people.
Where is UPSA SAS based?
UPSA SAS is headquartered in Rueil-malmaison, France, in the Europe region.
How does UPSA SAS make money?
One revenue line is on record: pharmaceutical product sales.
Who are UPSA SAS's main competitors?
Direct peers on record are Perrigo Company, Bayer AG, Pierre Fabre, Sanofi, Haleon and Johnson & Johnson (McNeil Consumer Healthcare). Emerging players are Cooper Consumer Health and Pileje. Zambon is listed as a regional player. Merck KGaA is listed as a broad incumbent.
Does UPSA SAS have an API?
No public API is recorded for UPSA SAS.
What industry is UPSA SAS in?
UPSA SAS's product category is Consumer Pharmaceuticals (OTC / Self-Medication). Its primary akta.pro industry code is CRADAGAK, Women’s Health Supplements (Prenatal, Menopause, Hormonal), with a secondary code of CRADAGAE, Specialty Condition Supplements (Sleep, Stress, Heart, Joint, Gut, Immunity). Its NAICS code is 3254 and its SIC code is 5122.